A Phase 2 interventional study of Placebo and Upadacitinib in Rheumatoid Arthritis, sponsored by AbbVie. Completed at 63 sites in 16 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-07-30.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 10th largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 2, and was the 4th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18–65
AbbVie
Ages 18+
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 8 · Phase 4 3
First in 2012; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 300 across the 19 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 14th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2014, is one of 16 in phase 2, and was the 40th registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, from their registry updates:
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to compare the safety and efficacy of multiple doses of upadacitinib versus placebo in adults with moderately to severely active rheumatoid arthritis (RA) on stable background methotrexate therapy who had not shown an adequate response to methotrexate alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have active RA as defined by the following minimum disease activity criteria:
Except for MTX, subjects must have discontinued all oral disease-modifying anti-rheumatic drugs (DMARDs) prior to Baseline Visit as specified below or for at least five times the mean terminal elimination half-life of a drug, whichever is longer:
Exclusion Criteria:
Screening laboratory values meeting the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo capsules twice daily for 12 weeks.
Drug: Placebo
Participants received 3 mg upadacitinib twice daily (BID) for 12 weeks.
Drug: Upadacitinib
Participants received 6 mg upadacitinib twice daily (BID) for 12 weeks.
Drug: Upadacitinib
Participants received 12 mg upadacitinib twice daily (BID) for 12 weeks.
Drug: Upadacitinib
Participants received 18 mg upadacitinib twice daily (BID) for 12 weeks.
Drug: Upadacitinib
Participants received 24 mg upadacitinib once daily (QD) for 12 weeks.
Drug: Upadacitinib
Tablets for oral administration
Tablets for oral administration
Also known as: ABT-494
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 50% improvement in 68-tender joint count; * ≥ 50% improvement in 66-swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician's global assessment of disease activity * Patient's global assessment of disease activity * Patient's assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale (VAS) from 0 to 100 mm). DAS28(CRP) scores range from 0 to approximately 10 where higher scores indicate more disease activity. LDA is defined as a DAS28(CRP) score \< 3.2.
Time frame: Week 12
Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12
The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale from 0 to 100 mm). DAS28(CRP) scores range from 0 to 10 where higher scores indicate more disease activity. CR is defined as a DAS28(CRP) score \< 2.6.
Time frame: Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12
The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA is defined as a CDAI score ≤ 10.
Time frame: Week 12
Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12
The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. CR is defined as a CDAI score ≤ 2.8.
Time frame: Week 12
A total of 300 adults with rheumatoid arthritis (RA) were enrolled at 59 study sites located in 16 countries.
| Milestone | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Started | 50 | 50 | 50 | 50 | 50 | 50 |
| Received study drug | 50 | 50 | 50 | 50 | 50 | 49 |
| Completed | 45 | 49 | 44 | 47 | 43 | 45 |
| Not completed | 5 | 1 | 6 | 3 | 7 | 5 |
| Withdrew: Adverse event | 1 | 1 | 1 | 1 | 5 | 1 |
| Withdrew: Withdrawal by subject | 4 | 0 | 5 | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Randomized in error | 0 | 0 | 0 | 0 | 0 | 1 |
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 50.0 | 64.6 | 73.5 | 81.6 | 76.6 | 81.6 |
A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 50% improvement in 68-tender joint count; * ≥ 50% improvement in 66-swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician's global assessment of disease activity * Patient's global assessment of disease activity * Patient's assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 19.6 | 39.6 | 49.0 | 50.0 | 44.7 | 43.8 |
A participant was a responder if the following 3 criteria for improvement from baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 6.5 | 23.4 | 30.6 | 16.0 | 27.7 | 25.0 |
The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale (VAS) from 0 to 100 mm). DAS28(CRP) scores range from 0 to approximately 10 where higher scores indicate more disease activity. LDA is defined as a DAS28(CRP) score \< 3.2.
| percentage of participants | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 | 21.3 | 49.0 | 57.1 | 46.0 | 51.0 | 42.9 |
The disease activity score-28-CRP (DAS28 \[CRP\]) assesses RA disease activity based on a continuous scale of combined measures of 28 tender joint counts (TJC28), 28 swollen joint counts (SJC28), C-reactive protein (CRP), and the patient global assessment of disease activity (measured on a visual analog scale from 0 to 100 mm). DAS28(CRP) scores range from 0 to 10 where higher scores indicate more disease activity. CR is defined as a DAS28(CRP) score \< 2.6.
| percentage of participants | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12 | 14.9 | 36.7 | 38.8 | 34.0 | 42.9 | 22.4 |
The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA is defined as a CDAI score ≤ 10.
| percentage of participants | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12 | 21.3 | 40.8 | 40.8 | 40.0 | 49.0 | 36.7 |
The clinical disease activity index (CDAI) is a composite index for assessing disease activity based on the summation of the counts of TJC28 and SJC28, patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. CR is defined as a CDAI score ≤ 2.8.
| percentage of participants | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12 | 4.3 | 12.2 | 14.3 | 6.0 | 14.3 | 6.1 |
Collected over From the first dose of study drug until 30 days after last dose (up to 16 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/50 (0%) | 0/50 (0%) | 2/50 (4%) |
| Upadacitinib 3 mg BID | 0/50 (0%) | 0/50 (0%) | 5/50 (10%) |
| Upadacitinib 6 mg BID | 0/50 (0%) | 2/50 (4%) | 7/50 (14%) |
| Upadacitinib 12 mg BID | 0/50 (0%) | 1/50 (2%) | 17/50 (34%) |
| Upadacitinib 18 mg BID | 0/50 (0%) | 3/50 (6%) | 6/50 (12%) |
| Upadacitinib 24 mg QD | 0/49 (0%) | 2/49 (4.1%) | 6/49 (12.2%) |
| Event | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| FOREARM FRACTUREInjury, poisoning and procedural complications | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 |
| HEAD INJURYInjury, poisoning and procedural complications | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 |
| SYNCOPENervous system disorders | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 |
| PYREXIAGeneral disorders | 0/50 | 0/50 | 0/50 | 0/50 | 1/50 | 0/49 |
| PNEUMONIAInfections and infestations | 0/50 | 0/50 | 0/50 | 1/50 | 0/50 | 0/49 |
| OSTEONECROSISMusculoskeletal and connective tissue disorders | 0/50 | 0/50 | 1/50 | 0/50 | 0/50 | 0/49 |
| LUNG NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/50 | 0/50 | 1/50 | 0/50 | 0/50 | 0/49 |
| SCIATICANervous system disorders | 0/50 | 0/50 | 0/50 | 0/50 | 1/50 | 0/49 |
| OVARIAN CYSTReproductive system and breast disorders | 0/50 | 0/50 | 0/50 | 0/50 | 1/50 | 0/49 |
| Event | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD |
|---|---|---|---|---|---|---|
| INFLUENZAInfections and infestations | 0/50 | 0/50 | 0/50 | 4/50 | 1/50 | 0/49 |
| NASOPHARYNGITISInfections and infestations | 1/50 | 1/50 | 2/50 | 4/50 | 2/50 | 3/49 |
| LEUKOPENIABlood and lymphatic system disorders | 0/50 | 0/50 | 0/50 | 3/50 | 1/50 | 0/49 |
| DIARRHOEAGastrointestinal disorders | 0/50 | 0/50 | 1/50 | 3/50 | 1/50 | 1/49 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 0/50 | 0/50 | 0/50 | 3/50 | 2/50 | 1/49 |
| DYSLIPIDAEMIAMetabolism and nutrition disorders | 0/50 | 1/50 | 0/50 | 3/50 | 0/50 | 0/49 |
| BACK PAINMusculoskeletal and connective tissue disorders | 0/50 | 1/50 | 3/50 | 1/50 | 0/50 | 1/49 |
| HEADACHENervous system disorders | 1/50 | 2/50 | 1/50 | 3/50 | 0/50 | 1/49 |
| COUGHRespiratory, thoracic and mediastinal disorders | 0/50 | 1/50 | 1/50 | 3/50 | 1/50 | 0/49 |
All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 54.5 ± 11.51 | 53.1 ± 12.15 | 54.8 ± 12.47 | 55.7 ± 11.65 | 54.6 ± 13.65 | 56.2 ± 11.79 | 54.8 ± 12.16 |
| Age, Customized(Participants) | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD | Total |
|---|---|---|---|---|---|---|---|
| 18 to < 45 years | 9 | 11 | 9 | 7 | 13 | 7 | 56 |
| 45 to < 65 years | 32 | 30 | 30 | 32 | 25 | 27 | 176 |
| ≤ 65 years | 9 | 9 | 11 | 11 | 12 | 15 | 67 |
| Sex: Female, Male(Participants) | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Female | 38 | 40 | 34 | 41 | 42 | 42 | 237 |
| Male | 12 | 10 | 16 | 9 | 8 | 7 | 62 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 8 | 17 | 17 | 7 | 8 | 68 |
| Not Hispanic or Latino | 39 | 42 | 33 | 33 | 43 | 41 | 231 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Upadacitinib 3 mg BID | Upadacitinib 6 mg BID | Upadacitinib 12 mg BID | Upadacitinib 18 mg BID | Upadacitinib 24 mg QD | Total |
|---|---|---|---|---|---|---|---|
| White | 50 | 48 | 49 | 48 | 49 | 49 | 293 |
| Black or African American | 0 | 1 | 1 | 1 | 0 | 0 | 3 |
| Multi-race | 0 | 1 | 0 | 1 | 1 | 0 | 3 |
Plan to share: Undecided
Ran from Mar 2014 to primary completion in Jul 2015, 15 months.
Results were first posted in Oct 2019, 4 years 3 months after primary completion. A results delay was requested in Jun 2016.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 15 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib